tradingkey.logo
搜索

Pharming Group NV

PHAR
添加自选
12.600USD
-0.350-2.70%
收盘 11-13 16:00(美东)
891.80M总市值
0.00市盈率 TTM

关于 Pharming Group NV 公司

Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Pharming Group NV 简介

公司代码PHAR
公司名称Pharming Group NV
上市日期Jul 02, 1998
CEOChouraqui (Fabrice)
员工数量- -
证券类型Depository Receipt
年结日- -
公司地址Darwinweg 24
城市LEIDEN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Netherlands
邮编2333 CR
电话31715247400
网址https://www.pharming.com/
公司代码PHAR
上市日期Jul 02, 1998
CEOChouraqui (Fabrice)

Pharming Group NV公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Barbara Yanni, J.D.
Ms. Barbara Yanni, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Ms. Leverne Marsh
Ms. Leverne Marsh
Interim Co-Chief Executive Officer, Chief Commercial Officer
Interim Co-Chief Executive Officer, Chief Commercial Officer
--
--
Ms. Ines Bernal
Ms. Ines Bernal
Chief People Officer
Chief People Officer
--
--
Mr. Kenneth Lynard
Mr. Kenneth Lynard
Interim Co-Chief Executive Officer, Chief Financial Officer
Interim Co-Chief Executive Officer, Chief Financial Officer
--
--
Ms. Jabine van Der Meijs, Pharm.D.
Ms. Jabine van Der Meijs, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Barbara Yanni, J.D.
Ms. Barbara Yanni, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--

常见问题

Pharming Group NV的前五大股东是谁?

Pharming Group NV 的前五大股东如下:Mr. Stephen (Steve) Toor

有多少机构持有Pharming Group NV(PHAR)的股份?

截至2026Q1,共有22家机构持有Pharming Group NV的股份,合计持有的股份价值约为135.73K,占公司总股份的0.19%。与2025Q4相比,机构持股有所增加,增幅为61813.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有